HOME >> BIOLOGY >> NEWS
Moderate exercise may delay congestive heart failure, CU-Boulder study suggests

A new University of Colorado at Boulder study involving laboratory rats that indicates low-intensity exercise may significantly delay the onset of congestive heart failure appears to have some promising implications for humans.

According to Professor Russell Moore of CU-Boulder's integrative physiology department who led the study, lab rats carrying the genetic characteristics for spontaneously developing heart failure were shown to live significantly longer if they exercised moderately on a treadmill. The exercise protocol, the equivalent of daily, leisurely strolls in humans, extended the life expectancy of the rat study group by at least 10 percent to 15 percent, according to the study.

"Assuming the results are applicable to humans, low-intensity exercise is likely to have benefits to humans in early stages of congestive heart failure," he said.

The study was published in the November 2005 issue of the American Journal of Physiology -- Heart and Circulatory Physiology. The study was co-authored by CU-Boulder doctoral student Craig Emter, Associate Professor Sylvia McCune, Research Associate Genevieve Sparagna and Ohio State University Professor Judith Radin.

"Our study, coupled with several human studies conducted elsewhere, shows a definite trend indicating that moderate intensity exercise has a potential role in stemming the downward spiral in heart failure," he said.

Moore said a unique feature of the CU-Boulder study was that the delay in the onset of CHF in the rats through moderate exercise was accomplished without reducing hypertension, or high blood pressure, in the animals. Most people in the early stages of development of heart failure also have hypertension, which is regularly treated to help improve the prognosis of CHF sufferers, said Moore.

Although several human studies in the last 10 to 20 years have shown that moderate exercise does not appear to harm CHF sufferers, the positive benefits
'"/>


8-Dec-2005


Page: 1 2 3

Related biology news :

1. Moderate drinking may help older women live longer
2. Moderate drinking may boost memory, study suggests
3. Moderate lifetime reductions in LDL cholesterol dramatically reduce risk of heart disease
4. Moderate alcohol consumption enhances the formation of new nerve cells
5. Moderate aerobic exercise improves cardiovascular and nervous system function in HIV+
6. Cardio exercise benefits in male vs. female hearts
7. Caffeine and exercise can team up to prevent skin cancer
8. Adult survivors of childhood leukemia exercise less, worsening high risk for obesity and illness
9. New clue into how diet and exercise enhance longevity
10. Exercise, exercise, rest, repeat -- how a break can help your workout
11. Losing weight after pregnancy -- diet and exercise better than diet alone

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
Cached News: